Together, the results above suggest that adjunctive ZOL/IL-2 (Group-2) or IL-2 (Group-3) administrations after MDR-TB infection and TB drug treatment led to milder MDR-TB pathology/lesions than TB drug alone and saline controls. This evidence concerns the gene IL2 and tuberculosis.